OncoSynergy has joined forces with the Musella Foundation to raise funds for the company's FDA approved Phase 1 clinical trial in recurrent glioblastoma.
OncoSynergy is a biotechnology company developing innovative therapeutics to improve outcomes for patients suffering from the worst cancers...
OncoSynergy is ready to bring its innovative solution to patients. Our goal is to raise at least $60,000 to fund treatment of at least 1 patient...
Our mission is led by Co-Founder and CEO, Dr. Anne-Marie Carbonell, a physician trained in neurosurgery...
Key to the trial is OncoSynergy's innovative therapy, OS2966, an anti-CD29 immunotherapy...
Please donate by using the form on the right. You can also send a check made out to "Musella Foundation" with "OncoSynergy GBM Trial Fund" in the memo...
For more details on this treatment go to: Oncosynergy.com
If you do donate, please consider checking to see if your employer has a corporate match policy!